Physician profile
Glenn Davison
NPI 1518924513
$118,424.39
in general payments reported to CMS, 2019-2025
47 companies · $4,411 in 2025
The $4,411 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $17K · 2021: $20K · 2022: $11K · 2023: $6,624 · 2024: $9,496 · 2025: $4,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,015 · Travel and Lodging: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,350.00 |
| Food and Beverage | $6,014.94 |
| Travel and Lodging | $1,167.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $61,476.94 | 2019-2022 | |
| Esperion Therapeutics, INC. | $39,258.70 | 2020-2025 | Nexletol, Nexlizet |
| Medicure Pharma INC. | $8,111.07 | 2019-2025 | Zypitamag |
| Boston Scientific Corporation | $1,206.85 | 2019-2025 | Watchman Access System, Watchman Flx, Accolade Sr |
| Novartis Pharmaceuticals Corporation | $1,050.55 | 2019-2025 | |
| Pfizer INC. | $797.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $776.55 | 2019-2024 | Xarelto |
| Amgen INC. | $552.01 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $485.92 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $459.85 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $379.38 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $357.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.26 | 2019-2025 | Jardiance |
| Cvrx, INC. | $292.04 | 2023-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $290.68 | 2019-2025 | Camzyos, Eliquis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.